Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | FDPS | P14324 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28668979 | 0.85 | ALDH1A1 (0.78) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL12259157 | 0.83 | FDPS (0.71) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL4267533 | 0.83 | NPC1 (0.64) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL28648496 | 0.83 | ALDH1A1 (0.74) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7606253 | 0.83 | VCP (0.60) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7606257 | 0.83 | VCP (0.60) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6585008 | 0.82 | FDPS (0.55) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6798515 | 0.82 | NPC1 (0.54) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13220785 | 0.82 | ALDH1A1 (0.72) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL5096223 | 0.82 | ALDH1A1 (0.72) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-0968179-B1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6277849-B1 | FOR PROTECTION OF PLANTS AGAINST PHYTOPATHOGENIC MICROORGANISM INFESTATION | SYNGENTA CROP PROTECTION, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-0968179-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | Novartis AG (CH) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998038161-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | NOVARTIS AG (CH) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | ALDH1A1 178/4885NPC1 1144/4885RAB9A 2459/4885 |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | ALDH1A1 178/4885NPC1 1144/4885RAB9A 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.